Adherium Receives Additional U.S. FDA 510(k) Clearance, Setting in Motion a Full U.S. Consumer Launch of the Hailie™ Solution

/in

26 Jul 2018 San Mateo, CA – July 26, 2018:  Adherium (ASX: ADR), an award-winning digital health platform that improves medication adherence, patient outcomes and engagement, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its Hailie™ sensor for use with ProAir® HFA, Ventolin® HFA and Flovent® […]

Read more

Destiny Pharma announces positive data from XF-73 Phase 1 skin irritation study

/in

Positive data supports product opportunities for XF-73 in dermal infection indications Data also supports planned Phase 2 clinical trial of XF-73 nasal gel for the prevention of post-surgical infection Brighton, United Kingdom – 26 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the […]

Read more

Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates

/in

Research to investigate potential antimicrobial candidates against biofilms Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The […]

Read more

Adherium Announces Patient Program with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

/in

10 Jul 2018 San Mateo, CA – July 10, 2018: Adherium (ASX: ADR), a leading digital health company that improves medication adherence and patient outcomes, today announced a patient program with Connecticut Children’s Medical Center to help patients with asthma manage their condition with Adherium’s technology, the Hailie™ solution. Connecticut Children’s Medical Center’s close work with the […]

Read more

Bipartisan bill proposes new ‘pull’ incentives for priority antibiotics

/in

Representatives in the US House of Representatives yesterday introduced a bipartisan bill to encourage the development of new antibiotics, a move one expert called the most important antibiotic legislation in a generation. Currently, only a few large drug companies are involved in antibiotic research and development, because the cost of developing the drugs is so […]

Read more